Xiao Wang, MD, MHS
About
Research
Publications
2026
Medicare Insurance Type and Broad Genomic Profiling in Metastatic Cancer
Chow R, Rothen J, Long J, Soulos P, Wang X, Mamtani R, Ma S, Kunst N, Dinan M, Gross C. Medicare Insurance Type and Broad Genomic Profiling in Metastatic Cancer. JAMA Network Open 2026, 9: e2614919. PMID: 42201732, PMCID: PMC13216988, DOI: 10.1001/jamanetworkopen.2026.14919.Peer-Reviewed Original ResearchA Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic Profiling
Wang X, Long J, Rothen J, Huang S, Soulos P, Goldberg S, Robinson T, Ma S, Mamtani R, Presley C, Wang S, Kunst N, Gross C, Dinan M. A Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic Profiling. Journal Of The National Comprehensive Cancer Network 2026, 24: e257131. PMID: 41698347, PMCID: PMC13112471, DOI: 10.6004/jnccn.2025.7131.Peer-Reviewed Original ResearchThis study introduces Y-MATRIX, a taxonomy classifying genomic profiling results by clinical actionability, showing increased actionable findings in advanced lung cancer from 2017 to 2023.
2025
Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer
Nassar A, Farhat E, Abushukair H, Alchoueriy M, Salem S, Machaalani M, Adib E, Henske E, Babu P, Choueiri T, Rakaee M, Busund L, Takabe Y, Lau S, Rall K, Naqash A, Jansen C, Wang X, Challa P, Tarantino P, Partridge A, Tolaney S, Kwiatkowski D, Winer E. Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer. Journal Of The National Cancer Institute 2025, 118: 669-679. PMID: 41418409, DOI: 10.1093/jnci/djaf344.Peer-Reviewed Original ResearchMolecular Biomarker Testing Patterns and Turn-Around Time in US Patients with Advanced Non-Small Cell Lung Cancer
Wang X, Lee D, Yang S, Li Y, Soulos P, Gross C, Wang S, Chiang A. Molecular Biomarker Testing Patterns and Turn-Around Time in US Patients with Advanced Non-Small Cell Lung Cancer. Journal Of The National Comprehensive Cancer Network 2025, 23: 461-467. PMID: 41072474, PMCID: PMC13268203, DOI: 10.6004/jnccn.2025.7063.Peer-Reviewed Original ResearchAdoption of Broad Genomic Profiling in Patients With Cancer
Wang X, Rothen J, Huang S, Long J, Soulos P, Goldberg S, Mamtani R, Presley C, Kunst N, Ma S, Wang S, Gross C, Dinan M. Adoption of Broad Genomic Profiling in Patients With Cancer. JAMA Oncology 2025, 11: 666-668. PMID: 40244595, PMCID: PMC12006912, DOI: 10.1001/jamaoncol.2025.0499.Peer-Reviewed Original Research
2024
Antibiotic practice and stewardship in the management of neutropenic fever: a survey of US institutions
Wang X, Arya S, Patel S, Saw S, Decena M, Hirsh R, Pegues D, Ziegler M. Antibiotic practice and stewardship in the management of neutropenic fever: a survey of US institutions. Infection Control And Hospital Epidemiology 2024, 45: 1168-1175. PMID: 39087709, PMCID: PMC11611503, DOI: 10.1017/ice.2024.103.Peer-Reviewed Original ResearchBig Decisions on Small Cell Lung Cancer: A Focus on Clinical Care Updates and Patient Perspectives.
Wang X, Chiang A. Big Decisions on Small Cell Lung Cancer: A Focus on Clinical Care Updates and Patient Perspectives. American Society Of Clinical Oncology Educational Book 2024, 44: e432520. PMID: 38830134, DOI: 10.1200/edbk_432520.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2023
Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma
Marmarelis M, Wang X, Roshkovan L, Grady C, Miura J, Ginsberg M, Ciunci C, Egger J, Walker S, Cercek A, Foote M, Litzky L, Nash G, Haas A, Karakousis G, Cengel K, Katz S, Zauderer M, Langer C, Offin M. Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma. JAMA Network Open 2023, 6: e232526. PMID: 36897589, PMCID: PMC10942662, DOI: 10.1001/jamanetworkopen.2023.2526.Peer-Reviewed Original ResearchA Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer
Iams W, Balbach M, Phillips S, Sacher A, Bestvina C, Velcheti V, Wang X, Marmarelis M, Sethakorn N, Leal T, Sackstein P, Kim C, Robinson M, Mehta K, Hsu R, Nieva J, Patil T, Camidge D. A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer. Clinical Lung Cancer 2023, 24: 228-234. PMID: 36841727, PMCID: PMC10234144, DOI: 10.1016/j.cllc.2023.01.009.Peer-Reviewed Original Research
2022
A single-center retrospective cohort study of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma
Wang X, Katz S, Miura J, Karakousis G, Roshkovan L, Walker S, McNulty S, Ciunci C, Cengel K, Langer C, Marmarelis M. A single-center retrospective cohort study of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma. PLOS ONE 2022, 17: e0275187. PMID: 36174024, PMCID: PMC9521908, DOI: 10.1371/journal.pone.0275187.Peer-Reviewed Original Research
Clinical Trials
Current Trials
AACR Adaptive Biomarker-Driven Organ Preservation Trial In Gastroesophageal Adenocarcinomas (AACR-ADOPT-GEA)
IRB ID2000041840RoleSub InvestigatorPrimary Completion Date06/01/2028Recruiting ParticipantsA Phase 1a/b, Multicenter, Open-label, First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
IRB ID2000042250RoleSub InvestigatorPrimary Completion Date06/30/2027Recruiting ParticipantsA Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05)
IRB ID2000040953RoleSub InvestigatorPrimary Completion Date05/01/2027Recruiting ParticipantsA Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms
IRB ID2000041573RoleSub InvestigatorPrimary Completion Date12/31/2027Recruiting ParticipantsA Phase I/II, Randomized, Multi-site Trial to Investigate the Efficacy and Safety of BNT314 in Combination With BNT327 and Chemotherapy in Participants With Metastatic Colorectal Cancer
IRB ID2000040952RoleSub InvestigatorPrimary Completion Date12/01/2030Recruiting Participants
Academic Achievements & Community Involvement
Clinical Care
Overview
Xiao Wang, MD, is a medical oncologist who cares for adults with cancers of the digestive system, including cancers of the colon, rectum, esophagus, stomach, pancreas, liver, and bile ducts. He works with patients and their families throughout diagnosis, treatment, and survivorship.
Dr. Wang offers a range of treatments, including chemotherapy, immunotherapy, and targeted therapies that act on specific changes in cancer cells. After patients complete their cancer treatments, Dr. Wang also manages ways to monitor for and reduce the risk of cancer recurrence. He aims to provide care that is patient-centered, compassionate, and thorough. He takes time to explain each person’s diagnosis and treatment options, helping them understand what to expect and supporting them in making decisions that fit their goals and values.
“I often tell patients that my main goal is to treat them, not just their cancer,” he says. “Cancer care can feel like a new language – a slew of acronyms and jargon – and I always try to remind myself that a ‘normal’ day for me could be the scariest and most overwhelming day of patients’ lives.”
As an instructor of medicine at Yale School of Medicine, Dr. Wang studies how to deliver precision cancer care more effectively. His research looks at gaps in the use of genetic tests on cancers to guide personalized treatments. He is part of Yale’s Cancer Outcomes, Public Policy and Effectiveness Research Center, where he examines how this type of testing affects treatment choices, patient outcomes, and the overall costs of cancer care. He is also focused on improving appropriate testing use at Yale so that patients can have the full benefit of modern technologies, new treatments, and clinical trials.
“My responsibility is to develop an effective, evidence-based treatment plan based on the latest scientific advances, and it is incredibly exciting to learn about and conduct new research to improve patient care,” he explains. “Just as important, though, is understanding what matters most to each person – their wishes, priorities, and fears, and the people and activities that bring them joy. I ask about these early so that our decisions reflect not only the disease, but also the individual. I want my patients to feel heard, respected, and supported, and to know that we are approaching their care as partners every step of the way.”
Dr. Wang earned his medical degree from Johns Hopkins School of Medicine. He completed his residency in internal medicine at the Hospital of the University of Pennsylvania, where he also worked as a hospitalist caring for people with blood and lymphatic cancers. He then completed fellowship training in medical oncology at Yale School of Medicine.
Clinical Specialties
News
News
- May 22, 2026
Center for GI Cancers CME Webinar Series: Pancreas Cancer
- February 16, 2026
Dr. Xiao Wang Joins Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center
- May 06, 2025
Genetic Test Underused in Cancer Care
- August 16, 2023
Welcome New Postdocs, Postgrads, Fellows, Faculty & Staff! (August 2023)
Get In Touch
Contacts
Yale School of Medicine
333 Cedar Street
New Haven, Connecticut 06510
United States
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.